TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Efprezimod Alfa (CD24Fc, MK-7110) as a Non-antiviral Immunomodulator in COVID-19 Treatment (MK-7110-007)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosed with coronavirus disease 2019 (COVID-19) and confirmed severe acute respiratory syndrome coronavirus 2 (SARS-coV-2) viral infection~* Severe or critical COVID-19, or National Institute of Allergy and Infectious Diseases (NIAID) 8-point ordinal score 2, 3 or 4 (Scale 2: requiring invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); Scale 3: non-invasive ventilation or high flow oxygen devices; Scale 4: supplemental oxygen support; a peripheral capillary oxygen saturation (SpO2) \</= 94% or tachypnea (respiratory rate \>/= 24 breaths/min). Intubation should be within 7 days~Exclusion Criteria:~* Participants who are pregnant, breastfeeding, or have a positive pregnancy test result before enrollment~* Participants previously enrolled in the efprezimod alfa study~* Intubation for invasive mechanical ventilation is over 7 days~* Documented acute renal or hepatic failure~* The investigator believes that participating in the trial is not in the best interests of the participant, or the investigator considers unsuitable for enrollment (such as unpredictable risks or subject compliance issues)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Efprezimod alfa (Type: EXPERIMENTAL): Participants receive single dose of 480 mg efprezimod alfa, diluted to 100 ml with normal saline, intravenous (IV) infusion in 60 minutes on Day 1.
- Placebo (Type: PLACEBO_COMPARATOR): Participants receive single dose of placebo as normal saline solution 100 ml, IV infusion in 60 minutes, on Day 1.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Metoclopramide Versus Ketorolac for Tension-type Headache

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Acute tension type headache~Exclusion Criteria:~* Contraindications to investigational medications~* Secondary cause of headache

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 64 Years
- Healthy Volunteers: f

Study Arms:
- Ketorolac (Type: ACTIVE_COMPARATOR): Ketorolac 30mg IVSS
- Metoclopramide (Type: ACTIVE_COMPARATOR): metoclopramide 20mg IVSS + diphenhydramine 25mg IVSS

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Open-label Extension Evaluating Methylphenidate Hydrochloride Extended Release in Adults With Attention Deficit/Hyperactivity Disorder

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Completion of the 40-week core study CRIT124D2302 and Week 40 (End of Study) assessments or Patients who meet predefined criteria for treatment failure, were withdrawn from the core study, and have completed core-study week 40 assessments (Premature Discontinuation Visit)~Exclusion Criteria:~1. Patients who, during the core study, developed any psychiatric condition that requires treatment with medication or that may interfere with study participation and /or study assessments.~2. Patients who during the core study developed cardiovascular disorders.~3. Pregnant women.~4. Patients who developed seizures during the core study.~5. Diagnosis of glaucoma, hyperthyroidism, pheochromocytoma.~6. Diagnosis or family history of Tourette's syndrome.~7. Patients who during the core study developed cerebrovascular disorders such as cerebral aneurysm, vascular abnormalities including vasculitis and stroke~Other protocol-defined inclusion/exclusion criteria may apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Ritalin LA (Type: EXPERIMENTAL): All participants started with Ritalin LA 20 mg/day and increased at weekly intervals in increments of 20 mg/day until reaching the patient's optimal dose 40, 60 or 80 mg/day).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Lactobacillus Reuteri DSM 17938 Versus Placebo in the Treatment of Infantile Colic

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Healthy term infant 21-90 days of age~2. Birth weight ≥2500 g~3. Exclusively breastfed (to reduce variability in the intestinal microflora attributable to dietary variations)~4. With colic symptoms (\>3 hours of crying on \>3 days per week) with debut 10 ± 5 days before enrollment~5. Gestational age between 37 and 42 weeks~6. Apgar score higher than 7 at 5 minutes~7. Written informed consent from a parent~Exclusion Criteria:~1. Any chronic illness or gastrointestinal disorder as judged by the pediatrician~2. Any history of antibiotic treatment or probiotic supplementation~3. Failure to obtain a written consent by parent/legal guardian~4. Participation in other clinical trials~5. Infants with acute illness~6. Subjects with allergies or family history of allergies to any of the ingredients of the study product or placebo

- Gender: ALL
- Minimum Age: 21 Days
- Maximum Age: 180 Days
- Healthy Volunteers: f

Study Arms:
- Biogaia L. reuteri DSM 17938 (Type: EXPERIMENTAL): Biogaia L. reuteri DSM 17938, probiotic infant drops (5 drops=10\^8 cfu),5 drops, once per day for 21 days.
- Probiotic Placebo (Type: PLACEBO_COMPARATOR): Placebo drops (sunflower oil, medium chain triglyceride oil, silicon chloride), 5 drops, once a day for 21 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of the Pharmacokinetic and Pharmacodynamic Biosimilarity of CHS-1701 (Coherus Pegfilgrastim) With Neulasta® (Pegfilgrastim)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Adult male or female of ages 18 to 50 inclusive~2. Body weight \> 50 kg (110 lb.) and body mass index between 18 and 32 kg/m2 inclusive~3. Medically healthy with clinically insignificant findings based on medical history, 12-lead ECG, and physical examination~4. Negative urine pregnancy test in women of childbearing potential~Exclusion Criteria:~1. Previous exposure to pegfilgrastim or filgrastim, or known allergy to PEG (polyethylene glycol)~2. Chemistry and hematology values outside protocol specified range~3. Current or previous cancer, diabetes, or any clinically significant cardiovascular, metabolic, renal, hepatic, gastrointestinal, hematologic, respiratory, dermatological, neurological, psychiatric, or other disorder~4. History of chronic or acute respiratory illness within the past 4 weeks~5. Positive urine drug or alcohol screen or unwillingness to abstain from alcohol or recreational drugs for the duration of study participation~6. No prescription or nonprescription drugs during the study~7. Participation in an investigational clinical study within 30 days prior to screening~8. Known or suspected allergic reaction to latex

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: t

Study Arms:
- CHS-1701/Neulasta (Type: EXPERIMENTAL): CHS-1701 followed by Neulasta (crossover)
- Neulasta/CHS-1701 (Type: EXPERIMENTAL): Neulasta followed by CHS-1701 (crossover)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Role of Omalizumab in Reducing the Incidence of Oxaliplatin-induced Hypersensitivity Reaction

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Clinically evident HSR to oxaliplatin, with symptoms of flushing, urticaria, pruritus, rash, and/or dyspnea without bronchospasm that emerge during or shortly after of oxaliplatin infusion~* Responding (complete or partial) or stable disease according to RECIST criteria while undergoing treatment with oxaliplatin containing regimen or need to resume an oxaliplatin based regimen in the setting of well-documented recent oxaliplatin hypersensitivity reaction~* Histologically confirmed stage IV GI cancer (AJCC 7th edition) currently sensitive to oxaliplatin containing chemotherapy regimen~* Age 18 years or older~* ECOG performance status 0-2~* Adequate bone marrow, liver, and kidney function. (WBC \> 1500 cells/uL, platelets \> 50,000/uL, ALT/AST \< 5xULN (unless due to liver metastasis), Creatinine \< 2.0 mg/ld)~* Willing to give written informed consent, adhere to the visit schedules and meet study requirements~Exclusion Criteria:~* Prior history of severe reactions to oxaliplatin as characterized by the presence of hemodynamic instability, significant respiratory symptoms or potential airway compromise~* History of hypersensitivity reaction to Xolair or any ingredient of Xolair~* Concurrent therapy with investigational agents~* Use of any other investigational agent in the last 15 days and all toxicity of prior therapy resolved~* Psychological, familial, or sociological condition potentially hampering compliance with the study protocol and follow-up schedule~* Women of childbearing potential not using the contraception method(s), as well as women who are breastfeeding~* Patients with severe medical conditions that in the view of the investigator prohibits participation in the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- OmalizumabTreatment Group (Type: EXPERIMENTAL): Omalizumab (Xolair) 300 mg SQ every 2 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Cost- Effectiveness and Quality of Life Assessment in Mood Disorder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. ages between 18 and 65;~2. BD current acute mixed episode;~3. total capacity to understand and respond to self-applied instruments;~4. the presence of symptoms in the last 30 days;~5. abstinence for at least 30 days for drug addicts.~Exclusion Criteria:~1. presence of Organic Brain Syndrome (OBS);~2. pregnancy or lactation;~3. criteria for psychiatric hospitalization.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Lithium (Type: ACTIVE_COMPARATOR): Subjects were randomized into three groups: (lithium, valproic acid, or carbamazepine).~Group (A) Started Lithium (900mg-1500mg)~Subjects evaluated for responsiveness every 2 weeks. Responsive to treatment patients remain in the same step. Max. step duration of 8 weeks.~1. First step: Monotherapy with Lithium (900-1500mg) Non responsive patients: 2nd step.~2. Second step: Randomization for lithium (900mg-1500mg) + valproic acid (1000mg-1500mg) OR lithium (900mg-1500mg) + carbamazepine (600mg-1200mg).~   Non responsive patients: 3rd step.~3. Third step: Crossover lithium (900mg-1500mg) + valproic acid (1000mg-1500mg) X lithium (900mg-1500mg) + carbamazepine (600mg-1200mg).~   Non responsive patients: 4th step.~4. Fourth step: Association with risperidone (1-6mg)
- Acid Valproic (Type: ACTIVE_COMPARATOR): Subjects were randomized into three groups: (lithium, valproic acid, or carbamazepine).~Group (B) Started Valproic Acid (1000mg-1500mg).~Subjects evaluated for responsiveness every 2 weeks. Responsive to treatment patients remain in the same step. Max. step duration of 8 weeks.~1. First step: Monotherapy with Valproic Acid (1000mg-1500mg) Non responsive patients: 2nd step.~2. Second step: Association with lithium (900mg-1500mg). Non responsive patients: 3rd step.~3. Third step: Crossover: lithium (900mg-1500mg) + carbamazepine (600mg-1200mg). Non responsive patients: 4th step.~4. Fourth step: Association with risperidone (1-6mg)
- Carbamazepine (Type: ACTIVE_COMPARATOR): Subjects were randomized into three groups: (lithium, valproic acid, or carbamazepine).~Group (C) Started Carbamazepine (600mg-1200mg).~Subjects evaluated for responsiveness every 2 weeks. Responsive to treatment patients remain in the same step. Max. step duration of 8 weeks.~1. First step: Monotherapy with Carbamazepine (600mg-1200mg). Non responsive patients: 2nd step.~2. Second step: Association with lithium (900mg-1500mg). Non responsive patients: 3rd step.~3. Third step: Crossover: lithium (900mg-1500mg) + valproic acid (1000mg-1500mg). Non responsive patients: 4th step.~4. Fourth step: Association with risperidone (1-6mg)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Ketamine Versus Fentanyl for Surgical Abortions

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Aged 14 years or older~* Voluntarily requesting surgical pregnancy termination~* Intrauterine pregnancy up to 13 weeks 6 days by transabdominal or transvaginal ultrasound performed on day of procedure~* Eligible for suction curettage~* English or Spanish speaking~* Able and willing to give informed consent and agree to terms of the study~Exclusion Criteria:~* Age less than 14 years~* Reaspiration procedure or failed medication abortion~* Early pregnancy loss~* Alcohol use disorder or acute alcohol intoxication~* Currently incarcerated~* Gestational age 14 weeks or more~* Requesting a specific pain regimen~* Premedication with misoprostol~* Contraindications or allergies to ketamine or fentanyl

- Gender: FEMALE
- Minimum Age: 14 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Ketamine (Type: EXPERIMENTAL): Participant will receive 2mg IV midazolam and 0.2-0.5mg/kg IV ketamine over 2 minutes, which can be repeated q5 minutes until appropriate analgesia is achieved.
- Fentanyl (Type: ACTIVE_COMPARATOR): Participant will receive 2mg IV midazolam and 0.5-1mcg/kg IV fentanyl over 2 minutes, which can be repeated q5m until appropriate analgesia is achieved.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Long-Term Oral Acyclovir Usage to Prevent Herpes Zoster Virus Infection After Bone Marrow Transplant

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* 10 years or older~* Both sex (male or female)~* Allogeneic transplant patient for hematologic malignancy or aplastic anemia~Exclusion Criteria:~* Previous intolerance to acyclovir~* Patients who are unavailable for follow-up~* Patients in whom drug compliance may be a problem~* Evidence of active VZV infection~* VZV infection in the initial 1 month after transplant~* Pregnant women, lactating women, or those not using adequate contraception~* Creatinine \> 3.0 mg/dl.

- Gender: ALL
- Minimum Age: 10 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Methylene Blue Combined With Artesunate or Amodiaquine for Malaria Treatment in Children of Burkina Faso: a Pilot Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion criteria:~* 6-10 year old children~* Ability to swallow tablets~* Uncomplicated malaria caused by P. falciparum~* Asexual parasites ≥ 2000/µl and \< 200000/µl~* Axillary temperature ≥ 37.5°C~* Burkinabe nationality~* Informed consent~Exclusion Criteria:~* Complicated or severe malaria~* Any apparent significant disease~* Anaemia (haematocrit \< 21%)~* Treated in the same trial before~* Antimalarial treatment prior to inclusion (last three days), except children having been treated with chloroquine

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 10 Years
- Healthy Volunteers: None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Bioavailability of Subcutaneous Dexmedetomidine

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Fluent skills in the Finnish language in order to be able to give informed consent and communicate with the study personnel.~* Age ≥ 18 years.~* Male gender.~* Weight ≥ 60 kg.~* Written informed consent from the subject.~Exclusion Criteria:~* Previous history of intolerance to the study drug or related compounds and additives.~* Concomitant drug therapy of any kind except paracetamol in the 14 days prior to the study.~* Existing or recent significant disease.~* History of any kind of drug allergy.~* Previous or present alcoholism, drug abuse, psychological or other emotional problems that are likely to invalidate informed consent, or limit the ability of the subject to comply with the protocol requirements.~* Donation of blood within six weeks prior to and during the study.~* Body weight \< 60 kg or BMI \> 30 kg / m2.~* Participation in any other clinical study involving investigational or marketed drug products concomitantly or within one month prior to the entry into this study.~* Smoking during one month before the start of the study or during the study period.~* Clinically significant abnormal findings in physical examination, ECG or laboratory screening

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- intravenous (Type: ACTIVE_COMPARATOR): 1 µg/kg dexmedetomidine (dexmedetomidine hydrochloride 100 microg/ml, Dexdor® Orion Oyj, Espoo, Finland) diluted in 10 ml of sodium chloride will be administered intravenously in 10 min at a constant rate using an infusion pump.
- subcutaneous (Type: ACTIVE_COMPARATOR): 1 µg/kg dexmedetomidine (dexmedetomidine hydrochloride 100 microg/ml, Dexdor® Orion Oyj, Espoo, Finland) will be administered subcutaneously undiluted.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of the Efficacy and Safety of ETC-1002 in Participants With Statin Intolerance

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~* A history of statin intolerance that began during statin treatment and resolved within 4 weeks of stopping the statin treatment~* For participants on current lipid-regulating drugs - LDL-C 100-220 milligrams per deciliter (mg/dL) and triglycerides \<350 mg/dL (prior to wash-out of all lipid-regulating drugs and supplements)~* For participants not on current lipid-regulating drugs - LDL-C 115-270 mg/dL and fasting TG \<400 mg/dL~Key Exclusion Criteria:~* Acute significant cardiovascular disease~* Poorly controlled hypertension

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- ETC-1002 (Type: EXPERIMENTAL): ETC-1002 treatment, once daily oral
- Placebo (Type: PLACEBO_COMPARATOR): Placebo treatment, once daily oral

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete